CellSight is a clinical stage PET imaging tools company that can increase probability of clinical success of immunotherapies by determining early if the immunotherapy is working in a cancer patient. Cancer immunotherapies that harness the body’s immune system to help fight cancer do not work for everyone; in fact, success rates can be as low as 20%! Many patients seem to get worse before symptoms ease and clinical benefit can be observed. CellSight’s PET tracers provide clinicians with imaging tools to assess immunotherapy response early in the treatment cycle to make informed decisions. Our tracers can be applied to any immune modulated diseases - RA, MS and others.